
Sean Nguyen, PharmD, discusses SENTRY data showing cefiderocol activity against resistant Pseudomonas VAP isolates and what it means for ICU care.

Sean Nguyen, PharmD, discusses SENTRY data showing cefiderocol activity against resistant Pseudomonas VAP isolates and what it means for ICU care.

Florin Draica, MD, MBA, of Shionogi on ensitrelvir PEP outcomes in patients infected at baseline despite negative antigen tests.

In a Q&A, Florin Draica, MD, MBA, explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to prioritize.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.

Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure outcomes beyond spending.

Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment should be tailored to each condition.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

Experts from AASLD’s The Liver Meeting 2026 share the research they expect to most shape liver care, from new biomarkers to emerging MASH drugs.

Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate and evidence strategies.

In part 2, Adam Colborn, JD, discussed federal health policy priorities, CMS fraud oversight, and how the midterm elections could shape legislation.

Mike Sharma, MD, discusses the asundexian trial’s broad patient population, results across stroke subtypes, and bleeding outcomes.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.

Phase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The University of Exeter’s David Halpin, MA, DPhil, explains why GOLD 2026 treats a single COPD exacerbation as a trigger to optimize care.

Michael Mina, MD, PhD, on why babies, immunocompromised patients, and the unvaccinated have the greatest need for a measles antibody.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.

Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.

Diabetes and functional dependence predicted 3-year graft loss after MASH liver transplant, while machine learning showed limited predictive power.

Gut-derived bile acids disrupt liver metabolism through LRH-1 before visible damage, pointing to new early biomarkers for fatty liver disease.

In nonobese patients in the ESSENCE trial, semaglutide improved metabolic dysfunction even with modest weight loss of 2% to 5%.

Àlvar Agustí, MD PhD; Jadwiga A. Wedzicha, MD; and 3 other experts say earlier diagnosis and intervention could most improve COPD outcomes within 5 years.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

SMART-MASH found about a third more patients with cirrhosis than Agile 4 while using costly fibrosis tests in only some patients.

Started at advanced fibrosis or cirrhosis, pegozafermin lowered liver collagen below baseline and prevented liver cancer in a MASH mouse model.

Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.